KR102049987B1 - Nkx3.2 단편 및 이를 함유하는 약학 조성물 - Google Patents

Nkx3.2 단편 및 이를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR102049987B1
KR102049987B1 KR1020170148493A KR20170148493A KR102049987B1 KR 102049987 B1 KR102049987 B1 KR 102049987B1 KR 1020170148493 A KR1020170148493 A KR 1020170148493A KR 20170148493 A KR20170148493 A KR 20170148493A KR 102049987 B1 KR102049987 B1 KR 102049987B1
Authority
KR
South Korea
Prior art keywords
ala
leu
gly
arg
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170148493A
Other languages
English (en)
Korean (ko)
Other versions
KR20180052103A (ko
Inventor
김대원
Original Assignee
아이씨엠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이씨엠 주식회사 filed Critical 아이씨엠 주식회사
Publication of KR20180052103A publication Critical patent/KR20180052103A/ko
Priority to KR1020190140236A priority Critical patent/KR102340761B1/ko
Application granted granted Critical
Publication of KR102049987B1 publication Critical patent/KR102049987B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y10S514/825—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020170148493A 2016-11-09 2017-11-09 Nkx3.2 단편 및 이를 함유하는 약학 조성물 Active KR102049987B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190140236A KR102340761B1 (ko) 2016-11-09 2019-11-05 Nkx3.2 단편 및 이를 함유하는 약학 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160149090 2016-11-09
KR20160149090 2016-11-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020190140236A Division KR102340761B1 (ko) 2016-11-09 2019-11-05 Nkx3.2 단편 및 이를 함유하는 약학 조성물

Publications (2)

Publication Number Publication Date
KR20180052103A KR20180052103A (ko) 2018-05-17
KR102049987B1 true KR102049987B1 (ko) 2019-11-28

Family

ID=62110655

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020170148493A Active KR102049987B1 (ko) 2016-11-09 2017-11-09 Nkx3.2 단편 및 이를 함유하는 약학 조성물
KR1020170148509A Active KR102049978B1 (ko) 2016-11-09 2017-11-09 Nkx3.2 단편을 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학 조성물
KR1020190140236A Active KR102340761B1 (ko) 2016-11-09 2019-11-05 Nkx3.2 단편 및 이를 함유하는 약학 조성물
KR1020200144613A Active KR102342171B1 (ko) 2016-11-09 2020-11-02 Nkx3.2 단편 및 이를 함유하는 약학 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020170148509A Active KR102049978B1 (ko) 2016-11-09 2017-11-09 Nkx3.2 단편을 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학 조성물
KR1020190140236A Active KR102340761B1 (ko) 2016-11-09 2019-11-05 Nkx3.2 단편 및 이를 함유하는 약학 조성물
KR1020200144613A Active KR102342171B1 (ko) 2016-11-09 2020-11-02 Nkx3.2 단편 및 이를 함유하는 약학 조성물

Country Status (9)

Country Link
US (2) US11235025B2 (enExample)
EP (2) EP3539978B1 (enExample)
JP (2) JP6991593B2 (enExample)
KR (4) KR102049987B1 (enExample)
CN (2) CN110036023B (enExample)
AU (2) AU2017358282C1 (enExample)
CA (1) CA3042186C (enExample)
ES (2) ES2987020T3 (enExample)
WO (1) WO2018088813A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060947B1 (fr) * 2016-12-28 2025-12-26 Ynsect Procede de traitement d'insectes comprenant la separation des cuticules de la partie molle des insectes puis la separation de la partie molle en trois fractions
CA3112915A1 (en) * 2018-10-19 2020-04-23 Icm Co., Ltd. Pharmaceutical composition for treating retinal diseases, comprising nkx3.2 and fragment thereof as active ingredients
KR102336515B1 (ko) * 2018-10-25 2021-12-07 애니젠 주식회사 부포린 유도체 및 이의 용도
CN112409454B (zh) * 2020-11-04 2022-07-05 青岛农业大学 一种法氏囊七肽及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097057A2 (en) * 2011-01-11 2012-07-19 Tufts University Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
BR112012004777A2 (pt) * 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
WO2011093647A2 (en) * 2010-01-26 2011-08-04 Industry-Academic Cooperation Foundation, Yonsei University Genes implicated in osteoarthritis and use thereof
KR101150900B1 (ko) * 2010-01-26 2012-05-30 연세대학교 산학협력단 퇴행성 관절염 치료 조성물
KR101150990B1 (ko) 2010-06-19 2012-06-13 김유정 슬롯리스 고정자를 갖는 브러시리스 직류 모터
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
CA2915296A1 (en) * 2013-06-11 2015-02-26 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
KR102044530B1 (ko) 2017-04-21 2019-11-14 아이씨엠 주식회사 Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097057A2 (en) * 2011-01-11 2012-07-19 Tufts University Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
US20140004047A1 (en) 2011-01-11 2014-01-02 Tufts University Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI Reference Sequence: XP_011839517.1 (2015. 3.30.)]*

Also Published As

Publication number Publication date
JP6991593B2 (ja) 2022-01-12
US11235025B2 (en) 2022-02-01
KR20190126753A (ko) 2019-11-12
US20200188480A1 (en) 2020-06-18
EP3835311C0 (en) 2024-08-28
KR102342171B1 (ko) 2021-12-23
AU2020207879B2 (en) 2021-04-15
CA3042186A1 (en) 2018-05-17
EP3539978A2 (en) 2019-09-18
EP3539978A4 (en) 2020-08-05
JP7055455B2 (ja) 2022-04-18
AU2020207879A1 (en) 2020-08-13
WO2018088813A2 (ko) 2018-05-17
JP2021020962A (ja) 2021-02-18
ES2987020T3 (es) 2024-11-13
AU2017358282C1 (en) 2020-11-26
US20190351015A1 (en) 2019-11-21
EP3539978C0 (en) 2025-02-26
CA3042186C (en) 2021-06-15
KR20180052104A (ko) 2018-05-17
KR102049978B1 (ko) 2019-11-28
CN110036023A (zh) 2019-07-19
AU2017358282A1 (en) 2019-05-23
US11154590B2 (en) 2021-10-26
EP3539978B1 (en) 2025-02-26
AU2017358282B2 (en) 2020-07-30
JP2019535310A (ja) 2019-12-12
EP3835311B1 (en) 2024-08-28
CN115925865A (zh) 2023-04-07
KR20180052103A (ko) 2018-05-17
KR102340761B1 (ko) 2021-12-21
EP3835311A1 (en) 2021-06-16
WO2018088813A3 (ko) 2018-10-04
WO2018088813A9 (ko) 2018-11-15
KR20200129068A (ko) 2020-11-17
ES3009014T3 (en) 2025-03-25
CN110036023B (zh) 2023-01-10

Similar Documents

Publication Publication Date Title
KR102342171B1 (ko) Nkx3.2 단편 및 이를 함유하는 약학 조성물
EP4154914B1 (en) Modified ube3a gene for a gene therapy approach for angelman syndrome
KR20150022799A (ko) 류마티즘 관절염 예방 또는 치료 조성물
CN109072255A (zh) 用于治疗皮肤的伤口、病症和疾病的组合物和方法
AU2019304522B2 (en) Compositions for the treatment of sarcopenia or disuse atrophy
US12202869B2 (en) Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof
Kitano et al. EGF domain peptide of Developmentally regulated endothelial locus1 facilitates gene expression of extracellularly applied plasmid DNA
WO2023183840A1 (en) Decoy peptides for treating diseases or conditions modulated by interleukin-33
US20020142963A1 (en) Methods for increasing bone formation and enhancing bone accretion

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220905

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7